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OBJECTIVE — To evaluate whether the administration of metformin exerts any effects on
serum homocysteine (Hcy) levels in patients with polycystic ovary syndrome (PCOS) and
whethersupplementationwithfolateenhancesthepositiveeffectsofmetforminonthestructure
and function of the vascular endothelium.
RESEARCH DESIGN AND METHODS — A total of 50 patients affected by PCOS,
without additional metabolic or cardiovascular diseases, were enrolled in a prospective nonran-
domized placebo-controlled double-blind clinical study. They were grouped into two treatment
arms that were matched for age and BMI. Patients were treated with a 6-month course of
metformin (1,700 mg daily) plus folic acid (400 g daily; experimental group, n  25) or
placebo(controlgroup,n25).Completehormonalandmetabolicpatterns,serumHcy,folate,
vitamin B12, endothelin-1 levels, brachial artery diameter at the baseline (BAD-B) and after
reactive hyperemia (BAD-RH), ﬂow-mediated dilation, and intima-media thickness in both
common carotid arteries were evaluated.
RESULTS — After treatment, a signiﬁcant increase in serum Hcy levels was observed in the
controlgroupcomparedwiththebaselinevaluesandtheexperimentalgroup.Abeneﬁcialeffect
was observed in the concentrations of BAD-B, BAD-RH, ﬂow-mediated dilation, intima-media
thickness, and serum endothelin-1 in both groups. However, the results were improved more
signiﬁcantly in the experimental group than in the control subjects.
CONCLUSIONS — MetforminexertsaslightbutsigniﬁcantdeleteriouseffectonserumHcy
levels in patients with PCOS, and supplementation with folate is useful to increase the beneﬁcial
effect of metformin on the vascular endothelium.
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P
olycystic ovary syndrome (PCOS) is
a heterogeneous disorder character-
ized by hyperandrogenism, ovarian
dysfunction, and polycystic ovarian mor-
phology. Young patients with PCOS but
noadditionalriskfactorsforcardiovascu-
lar disease have a signiﬁcant impairment
of endothelial structure and function (1).
In particular, when compared with con-
trol subjects matched for age and BMI,
patients with PCOS had abnormal bra-
chial artery diameter at baseline (BAD-B)
and after reactive hyperemia (BAD-RH)
and showed abnormal ﬂow-mediated di-
lation (FMD) and an increased intima-
media thickness (IMT) in their common
carotid arteries (1). In addition, plasma
concentrations of endothelin-1 (ET-1), a
biochemical marker of endothelial func-
tion, were altered signiﬁcantly (1).
A subsequent clinical study showed
that a 6-month course of biguanidine
metformin improved these parameters of
endothelial structure and function signif-
icantly, which suggested that metformin
has a beneﬁcial effect in reducing the
long-term risk of cardiovascular disease
in patients with PCOS (2).
Moreover, in patients with type 2 di-
abetes,metforminhasbeendemonstrated
to increase serum levels of homocysteine
(Hcy) (3–5). Increased concentrations of
Hcy are a well-known risk factor for cor-
onary heart disease and stroke (6). The
acute effect of metformin on insulin sen-
sitivity could either increase serum Hcy
levels directly or induce malabsorption of
vitamin B12 indirectly (7). Other un-
known adjunctive mechanisms cannot be
excluded.
Based on these considerations, the
aim of the present study was to evaluate
whether the administration of metformin
exerts any effect on serum Hcy levels in
patients with PCOS and whether supple-
mentation with folate enhances the posi-
tive effects of metformin on the structure
andfunctionofthevascularendothelium.
RESEARCH DESIGN AND
METHODS— The procedures used
during the study were in accordance with
the guidelines of the Helsinki Declaration
on human experimentation and those of
theGoodClinicalPracticeguidelines.The
study was approved by the institutional
reviewboardsofthe“MagnaGraecia”and
“Federico II” Universities of Catanzaro
and Naples, Italy, respectively. The study
protocol was explained carefully to each
woman, and written consent was ob-
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Obstetrics and Gynecology, University “Magna Graecia” of Catanzaro, Catanzaro,
Italy; the
2Department of Clinical Medicine, Cardiovascular and Immunological Sciences, University
“FedericoII”ofNaples,Naples,Italy;the
3DepartmentofObstetricsandGynecology,University“Federico
II”ofNaples,Naples,Italy;the
4DepartmentofEndocrinology,University“FedericoII”ofNaples,Naples,
Italy; and
5Chair of Endocrinology, University “Parthenope” of Naples, Naples, Italy.
Corresponding author: Stefano Palomba, stefanopalomba@tin.it.
Received 13 August 2009 and accepted 12 November 2009. Published ahead of print at http://care.
diabetesjournals.org on 23 November 2009. DOI: 10.2337/dc09-1516. Clinical trial reg. no.
NCT00953355, clinicaltrials.gov.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLE
246 DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 care.diabetesjournals.orgtained from each participant before entry
into the study.
Patients
Between February 2004 and April 2006,
50 consecutive women with PCOS, who
had been referred as outpatients to the
two academic departments for the treat-
ment of oligomenorrhoea, were enrolled
inaprospectivenonrandomizedplacebo-
controlled double-blind clinical study.
The patients were allocated to one of
two study groups and were matched for
age and BMI. There were 25 participants
(control subjects) who received met-
formin and a placebo, whereas the re-
maining 25 patients (the experimental
group) received the experimental treat-
ment. The diagnosis of PCOS was based
ontheNationalInstitutesofHealth(NIH)
criteria (8).
Thefollowinggeneralexclusioncrite-
ria were considered: age 18 or 35
years; BMI 35 kg/m
2; neoplastic, meta-
bolic, endocrine, hepatic, renal or cardio-
vascular disorders, or other concurrent
medical illnesses; glucose intolerance;
malabsorptivedisorders;folateorvitamin
B12 deﬁciency; current or previous
(withinthelast6months)useofhormonal,
antidiabetic, or anti-obesity drugs; and in-
tention to adopt a diet and/or a speciﬁc
physical activity program.
All participants had a normal level of
physical activity and were nonsmokers;
none were known to abuse alcohol.
Study protocol
All participants (experimental and con-
trol groups) received metformin from the
thirddayofaprogesterone-inducedwith-
drawalbleeding(100mgnaturalprogester-
one intramuscularly) at a starting dose of
850 mg (one tablet daily before lunch) for
the ﬁrst week. The dose rose to 1,700 mg/
day thereafter (two tablets daily, one before
lunch and one before dinner).
Theexperimentalgroupalsoreceived
400 g folic acid daily (one tablet/day),
whereas the control group received an in-
ert cellulose powder placebo (one tablet/
day). Both folic acid and placebo tablets
were taken in association with the met-
formin therapy. Patients were blinded to
the treatment allocation (experimental or
control group).
Throughout the study, no lifestyle
modiﬁcation was implemented; indeed,
participants were instructed to follow
theirusualdietandphysicalactivity.Each
patient was also advised to use barrier
contraception throughout the study.
At entry into the study and after 6
months of treatment, all participants un-
derwent clinical and biochemical evalua-
tions and a cardiovascular examination.
All of the investigators involved in the
study were blinded to the treatment
allocation.
Clinical assessment
Clinical assessment consisted of anthro-
pometric measurements, which included
height, weight, BMI (ratio between the
weight and the square of the height), and
waist-to-hipratio(ratiobetweenthewaist
and the circumference of the hip), and an
assessment of the Ferriman-Gallwey
score.
Measurements of heart rate, systolic
blood pressure, and diastolic blood pres-
sure were also obtained. The systolic and
diastolic blood pressure levels were mea-
sured in the right arm by standard meth-
ods with the participants in a relaxed
sitting position, using a mercury sphyg-
momanometer. The average of six mea-
surements taken by two independent
examiners (each took three sets of mea-
surements) was used.
Transvaginal ultrasonography was
performed on each participant during the
same baseline visit by an experienced op-
erator (T.R.).
Daily physical activity was evaluated
for each participant with the use of a lei-
sure-time physical activity questionnaire
andacalculationoftheweeklyenergyex-
penditure score (total leisure-time physi-
cal activity level) in metabolic equivalents
per hour per week.
Diet and caloric intake were assessed
by an experienced clinical dietitian using
a self-administered semiquantitative vali-
dated food-frequency questionnaire and
software designed for the analysis of food
habits and the estimation of nutrient
and caloric intake (WinFood, release 1.5;
Medimatica, Martinsicuro, Teramo,
Italy).
All participants were instructed to
record in a personal daily diary the onset
of any adverse events, specifying their
characteristics (severity, duration, and
possible cause-effect relationship with
drug administration), the characteristics
of their menstrual cycles (length and
quantity), the number of skipped tablets,
and any changes in diet, physical activity,
or weight.
During the study, no monitoring of
ovulation was performed by ultrasonog-
raphy. However, ovulation was detected
by a plasma progesterone assay (10 ng/
ml, SI: 32 nmol/l) performed 7 days be-
fore the expected menses.
Biochemical assessment
During the early proliferative phase (sec-
ond to third day) of the progesterone-
induced uterine withdrawal bleeding, a
venousbloodsamplewastakenfromeach
participant between 8:00 and 9:00 A.M.
afterfastingfor12handrestinginbed,to
assess a complete hormonal proﬁle, lipid
pattern, serum ET-1, glucose and insulin
(at fasting and after a 2-h oral glucose tol-
erance test), Hcy, folate, and vitamin B12
levels.
In each participant, the homeostasis
model of assessment (HOMA), the fasting
glucose-to-insulin ratio (GIR) (mg/10
4
units), the area under the curve (AUC)
for glucose (AUCglucose) and insulin
(AUCinsulin), and the free androgen index
were calculated.
Serum levels of ET-1 were measured
by an enzyme-linked immunosorbent as-
say (Biomedica Gesellschft, Wien, Aus-
tria) with a sensitivity of 0.05 pmol/l and
intra- and interassay coefﬁcients of varia-
tion (CVs) of 4.5 and 6.9%, respectively
(1,2).
Serum Hcy levels were measured by
high-pressure liquid chromatography
(HPLC) (9). The sensitivity of the assay
forHcywas0.25mol/lserum,andthe
intra- and interassay CVs were 1 and 2%,
respectively.
The levels of vitamin B12 and folate
were analyzed by capillary electrophore-
sis (P/ACE 5000 system, Beckman
Coulter) (9). The intra- and interassay
CVs for the vitamin B12 assay were 6.7
and 7.4%, respectively, and 4.2 and
4.1%, respectively, for the folate assay.
Cardiovascular studies
All participants were studied during the
same visit in a comfortable supine posi-
tion in a quiet room, having fasted for at
least 8–12 h and been at rest for at least
4–6 h before the examination. Ambient
light and temperature were controlled
throughout the procedures (1,2).
Brachial artery reactivity and the IMT
ofthecommoncarotidarterieswerestud-
ied using a color Doppler ultrasound sys-
tem by an experienced ultrasonographer
(F.G.). Scans for the analysis of brachial
reactivity were taken over the dominant
brachial artery in a longitudinal orienta-
tion just proximal to the antecubital fossa
using a high-resolution 7.5-MHz linear
transducer. Blood ﬂow to the limb was
occluded by inﬂating a standard sphyg-
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mmHgabovesystolicbloodpressurefor4
min) to induce ischemia. The BAD-RH
was measured at 30 s, 1, 2, 3, and 4 min
after the subsequent deﬂation of the cuff.
In all studies, blood pressure in the con-
tralateral brachial artery was recorded at
regular intervals, and the electrocardio-
gram was monitored continuously (1,2).
BrachialarteryFMDwascalculatedas
the percentage change in brachial artery
diameter from baseline to 4 min after
deﬂation of the cuff. In our studies, the
intra- and inter-observer CVs for the re-
peated measurements of the resting arte-
rial diameter were 2.3 and 5.6%,
respectively (1,2).
Longitudinal ultrasonographic scans
ofthecarotidarterywereobtainedusinga
high-resolution 10-MHz linear probe. All
women were examined in the supine po-
sition with the head hyperextended and
turned away from the side being scanned.
Imageswereobtainedfromthedistalpor-
tionofbothcommoncarotidarteries,1–2
cm proximal to the carotid bulb and im-
mediately proximal to the origin of the
bifurcation (1,2).
The IMT of the posterior wall of both
commoncarotidarterieswasmeasuredas
the distance between the junction of the
lumen and intima and the junction of the
mediaandadventitiaattheendofdiastole
from the B-mode screen. The mean IMT
foreachsidewascalculatedastheaverage
of10measurementsmadeoftherightand
left carotid arteries using electronic cali-
pers. In our studies, the intra- and inter-
observer CVs for the repeated mea-
surements of IMT were 7.0 and 12.0%,
respectively (1,2).
Statistical analysis
The sample size was calculated on the as-
sumption that a difference of 0.1 mm in
IMT is clinically relevant because it pre-
dicts a 10–15% reduction in the risk of
future myocardial infarction and a 13–
18% reduction in the risk of future stroke
(10). Given that a mean IMT of 0.53 
0.09 (mm  SD) has been observed in
patients with PCOS (1,2), we needed to
enrollatleast23patientsineachgroupto
yieldastatisticallysigniﬁcantresultwitha
power of 90%. To allow for an unpredict-
able number of withdrawals, we decided
to enroll a total of 50 patients with the
expectationthatatleast23patientswould
be left in each group. The criterion for
signiﬁcance () was set at 0.05. The test
was two-tailed, which means that an ef-
fect in either direction would be inter-
preted. The power analysis and the
sample size calculation were performed
using SamplePower release 2.0 (SPSS,
Chicago, IL).
Considering the experimental study
design and the expected dropout rate,
data were analyzed by a per-protocol
analysis on the basis of the treatment re-
ceived and not on the treatment assign-
ment.Infact,wedecidedtostudythereal
effect of the treatments only in the sub-
jects who took their allocated therapy.
Forcategoricalvariables,Pearson’s
2
testwasperformed;Fisher’sexacttestwas
requiredwhen20%oftheexpectedval-
ues in the frequency tables were below
5.0.
The normal distribution of the data
for continuous variables was evaluated
with the Kolmogrov-Smirnov test. These
data were expressed as means  SD and
analyzed with an unpaired Student’st test
and the general linear model (GLM) for
a repeated measures analysis, with the
Bonferroni test for post hoc analysis as
required.
Bivariate two-tailed correlations were
performed when calculating the Spear-
man’s coefﬁcient (Spearman’s rho,r), and
the signiﬁcance of the correlation was set
atthe0.05leveltostudytherelationships
between the variations (	) in Hcy levels
(	-Hcy), in insulin sensitivity indexes
(	-HOMA, 	-GIR, 	-AUCinsulin/
AUCglucose), and in IMT (	-IMT).
Statistical signiﬁcance was set for all
analyses at P  0.05. The Statistics Pack-
age for the Social Sciences (SPSS 14.0.1;
SPSS, Chicago, IL) was used for all statis-
tical analyses.
RESULTS— All patients studied had a
“full-blown” PCOS phenotype, which
consisted of hyperandrogenism, oligo-
anovulation, and polycystic ovaries (11).
This was conﬁrmed by the identiﬁcation
of polycystic ovaries during transvaginal
ultrasonography in all of the participants
(11).
During the study, the two treatments
were tolerated well, and the total inci-
dence of adverse events was not signiﬁ-
cantly different between the two groups.
The rate of withdrawal was similar in the
two groups (two subjects in the experi-
mental group and one in the control
group). These three patients were ex-
cluded because they were not compliant
with the treatment, and their data were
not considered in the ﬁnal analysis.
Table 1 shows the clinical, hormonal,
and metabolic data at the baseline and af-
ter 6 months of treatment in both groups.
The proportion of lean (no patients in ei-
ther group), normal-weight (7/23
[30.4%] vs. 9/24 [37.5%]), overweight
(11/23 [47.8%] vs. 10/24 [41.7%]), and
obese (5/23 [21.7%] vs. 5/24 [20.8%])
patients was not different between the
groups (P  0.756).
Signiﬁcant (P  0.05) changes were
observedinbothgroups,withoutadiffer-
ence between them with respect to the
levels of serum testosterone and sex-
hormone binding globulin and for the
free androgen index compared with base-
line values (Table 1). Similarly, a signiﬁ-
cant (P  0.05) reduction in the levels of
insulin, HOMA, AUCinsulin, AUCglucose 
AUCinsulin, and LDL cholesterol and a sig-
niﬁcant increase in GIR were detected af-
ter 6 months of treatment in both groups,
with no difference between the two treat-
ment arms (Table 1).
In the control group, serum Hcy lev-
els were signiﬁcantly (P  0.05) higher
after treatment than the baseline values,
whereas no signiﬁcant change from base-
line was observed in the experimental
group (Table 1). In addition, a signiﬁcant
(P  0.05) difference in serum Hcy levels
was detected between the groups after
treatment (Table 1).
At the end of the study, no signiﬁcant
difference had been observed in the
length, frequency, or quantity of men-
struation between the two groups (data
not shown). In addition, no difference
was found between groups with regard to
the rate of ovulatory cycles (89/138
[64.5%] vs. 90/144 [62.5%]; P  0.728).
No further difference in any clinical,
hormonal, or metabolic parameter was
observed between or within the experi-
mental and control groups (Table 1).
Table 2 depicts the parameters of en-
dothelialstructureandfunctionthatwere
observedatbaselineandafter6monthsof
treatment in the two groups. No signiﬁ-
cant difference in any endothelial param-
eter was observed between the two
groups at baseline. After 6 months of
treatment, a signiﬁcant (P  0.05) reduc-
tion in the levels of BAD-B, BAD-RH,
IMT, and serum ET-1, and a signiﬁcant
(P  0.05) increase in FMD, were ob-
served in the two groups in comparison
with the baseline values (Table 2). In ad-
dition, signiﬁcant (P  0.05) differences
betweenthetwogroupsweredetectedfor
all these parameters (Table 2).
In both groups, no signiﬁcant corre-
lation was detected between 	-Hcy and
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r  0.704, P  0.412, for the experi-
mental and control groups, respectively),
	-GIR (r  0.587, P  0.189, and r 
0.604, P  0.242, for the experimental
and control groups, respectively), or
AUCglucose  AUCinsulin (r  0.765,
P  0.654, and r  0.678, P  0.547,
for the experimental and control groups,
respectively). Conversely, a signiﬁcant
correlation was observed between 	-Hcy
and 	-IMT in both the experimental (r 
0.504, P  0.042) and control (r 
0.632, P  0.039) groups.
CONCLUSIONS— Administration
of metformin exerted beneﬁcial effects on
the traditional cardiovascular risk factors
and reduced the morbidity and mortality
from cardiovascular events in patients
with type 2 diabetes (12). However, met-
formin also reduced serum levels of folate
and vitamin B12 and increased serum
Hcy levels in patients with diabetes
(13,14),evenafteronlyashortperiod(5).
Long-term administration of metformin
was shown to result in malabsorption of
vitamin B12 (15), although the correla-
tion between serum Hcy levels and ab-
sorption of folate or vitamin B12 was not
clear. Unexpectedly, the improved sensi-
tivity to insulin associated with met-
formin may increase plasma Hcy
Table 1—Clinical, hormonal, and metabolic data in PCOS patients treated with metformin plus supplementation with folate (experimental
group) or metformin plus placebo (control group) at study entry and after 6 months of treatment
Experimental (n  23) Control (n  24)
Baseline 6 Months Baseline 6 Months
Age (years) 26.9  3.1 27.0  2.8 26.4  2.8 26.6  3.0
BMI (kg/m
2) 27.9  2.6 27.8  2.9 28.1  3.1 27.9  3.4
Waist-to-hip ratio 0.82  0.3 0.82  0.4 0.84  0.5 0.83  0.6
Ferriman-Gallwey score 11.6  3.2 10.8  3.7 11.9  2.8 11.4  3.3
Leisure-time physical activity†
None 10 (43.5) 9 (39.1) 11 (45.8) 10 (40.0)
Light 5 (21.7) 6 (26.1) 6 (25.0) 5 (20.8)
Moderate 6 (26.1) 5 (21.7) 4 (16.7) 4 (16.7)
Strenuous 2 (8.7) 3 (13.0) 3 (12.5) 5 (20.8)
Total (metabolic equivalents per hour per week) 8.3  3.4 8.3  3.4 8.3  3.4 8.7  3.5
Heart beat (beats/min) 71.9  4.3 71.5  5.7 72.3  6.1 72.0  6.4
Systolic blood pressure (mmHg) 119.6  10.8 114.6  14.2 116.5  13.1 113.2  14.3
Diastolic blood pressure (mmHg) 70.7  9.8 68.7  6.5 71.5  6.9 71.3  7.2
Follicle-stimulating hormone (mIU/ml) 5.8  1.3 6.3  1.6 5.8  1.5 5.9  1.8
Luteinizing hormone (mIU/ml) 16.1  4.4 16.7  4.2 15.3  5.4 16.2  6.2
Thyroid-stimulating hormone (U/ml) 2.7  0.9 2.1  1.1 2.6  1.3 2.6  2.3
Prolactin (ng/ml) 9.0  2.0 8.4  2.1 7.9  2.3 8.2  2.7
17
-estradiol (pg/ml) 40.8  4.8 41.5  4.3 38.2  4.4 39.5  6.4
Progesterone (ng/ml) 0.8  0.1 0.7  0.2 0.8  0.3 0.8  0.4
17-OH-progesterone (g/l) 0.7  0.3 0.7  0.5 0.8  0.1 0.7  0.2
Total testosterone (ng/ml) 1.5  0.4 1.1  0.3* 1.6  0.3 1.3  0.4*
Androstenedione (ng/ml) 1.7  0.4 1.6  0.5 1.7  0.2 1.6  0.4
Dehydroepiandrosterone sulfate (ng/ml) 2,726.6  294.8 2,700.3  257.9 2,689.9  256.9 2,602.3  262.4
Sex-hormone binding globulin (nmol/l) 27.5  5.6 38.2  6.3* 28.4  6.9 40.2  7.3*
Free androgen index (%) 20.0  6.1 10.4  3.9* 21.2  7.1 12.0  5.2*
Fasting glucose (mg/dl) 84.7  9.0 82.6  7.2 79.3  10.4 80.3  11.2
Fasting insulin (U/ml) 14.6  5.3 10.2  4.0* 15.1  4.8 10.9  4.3*
GIR (mg/10
4 units) 8.9  5.2 11.1  6.6* 7.6  6.1 11.3  7.0*
HOMA 5.4  2.9 5.1  1.7* 4.9  3.7 4.2  3.1*
Oral glucose tolerance test
AUCglucose (mg/dl/120 min) 1,182.5  143.9 1,130.0  148.3 1,222.7  128.2 1,246.9  135.9
AUCinsulin (U/ml/120 min) 5,366.7  715.2 2,830.8  352.9* 5,401.7  891.2 2,538.4  365.8*
AUCglucose/AUCinsulin ratio 0.32  0.12 0.20  0.06* 0.37  0.01 0.21  0.11*
Total cholesterol (mg/dl) 150.8  42.5 146.7  38.7 143.1  30.9 141.9  43.2
HDL cholesterol (mg/dl) 85.1  19.3 86.7  15.5 90.8  16.9 91.2  17.3
LDL cholesterol (mg/dl) 73.5  19.4 66.6  18.7* 74.8  23.9 68.6  27.1*
Triglycerides (mg/dl) 132.9  26.6 124.0  26.6 123.6  26.7 126.4  27.6
Vitamin B12 (ng/ml) 379.3  108.1 384.9  118.3 379.3  108.1 364.7  123.4
Folate (nmol/ml) 8.5  2.9 8.9  3.1 8.6  2.4 8.2  3.2
Hcy (mol/l) 10.5  3.9 9.7  4.2 11.1  4.4 13.9  3.8*†
Data are means  SD or n (%). *P  0.05 vs. baseline. †P  0.05 vs. experimental group. The leisure-time physical activity level was graded into four categories:
1) no leisure-time physical activity; 2) light leisure-time physical activity most of the week; 3) moderate leisure-time physical activity (large increase in heart rate,
breathing, and perspiration) for at least 20 min once or twice a week; and 4) strenuous leisure-time physical activity for at least 20 min three times a week or more.
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abetes (6) or without diabetes (16).
Unlike the levels of serum Hcy in pa-
tients with diabetes, the response of se-
rum Hcy levels to the administration of
metformin in women affected by PCOS
was unclear, probably because of the het-
erogeneity of the studied populations
(17–19).Inagreementwithpreviousdata
(17,19),theresultsofthestudydescribed
hereinshowedasigniﬁcantincreaseinse-
rum Hcy levels after 6 months of met-
formin treatment in a heterogeneous
population with PCOS. Our ﬁndings
were not conﬁrmed by Yilmaz et al. (18),
whoobservedthattherewasnochangein
the concentration of plasma Hcy after the
administration of metformin in lean pa-
tients with PCOS. However, even if the
cohort studied in the latter trial was com-
prised of a well-selected sample, they did
not represent the broad spectrum of pa-
tients who have PCOS.
Our ﬁndings demonstrated that the
increase in plasma Hcy concentrations
that was attributable to metformin treat-
ment was not associated with any signiﬁ-
cant effect on the level of serum folate or
vitamin B12. In addition, no signiﬁcant
relationship was detected between 	-Hcy
and changes in the indexes of insulin sen-
sitivity, including 	-HOMA, 	-GIR, and
AUCglucose  AUCinsulin. These data sug-
gest that the increase in plasma Hcy can
be explained by factors that act in addi-
tion to metformin treatment to improve
insulin sensitivity. In fact, the administra-
tion of rosiglitazone, which is an insulin-
sensitizing drug that improves insulin
sensitivity more signiﬁcantly than met-
formin, resulted in the opposite physio-
logical effect to metformin because it
decreased serum Hcy levels (5).
In agreement with our previous data
(1,2), the current study conﬁrmed the
beneﬁcial effect of metformin on the
structure and function of the vascular en-
dothelium in young patients with PCOS.
After 6 months of treatment, BAD-B,
BAD-RH, IMT, and serum ET-1 levels
were signiﬁcantly lower than the baseline
values, whereas a signiﬁcant increase in
FMD was detected.
The results of folic acid supplementa-
tion in patients with PCOS who also re-
ceivedmetforminwereveryinteresting.A
previousunderpoweredrandomizedcon-
trolledstudy(20)showedthatserumHcy
levels were reduced by 21.2% after the
administration of folic acid and by 8.3%
after the administration of B-group vita-
mins in patients affected by PCOS who
had also been treated for 12 weeks with
metformin.Ourresultsconﬁrmedthesig-
niﬁcant reduction in serum Hcy levels af-
ter supplementation of metformin
treatment with 400 g folic acid daily, in
comparison with subjects who had re-
ceived a placebo. This represents a poten-
tial beneﬁcial effect in terms of reducing
the incidence of long-term adverse car-
diovasculareventsinpatientswithPCOS.
The effects of a reduction in serum
Hcylevelsonthevascularendotheliumin
patients affected by PCOS have not been
demonstrated previously. In the current
study, we reported a signiﬁcant correla-
tion between the variation in Hcy levels
and changes in the IMT after treatment
with metformin and folic acid.
To our knowledge, this is the ﬁrst
study to investigate the effects of supple-
mentation with folate in patients with
PCOS who are being treated with met-
formin. After 6 months of metformin
treatment with supplementation with fo-
lic acid, a signiﬁcant improvement was
observed in all the markers of structure
andfunctionofthevascularendothelium.
Moreinterestingly,theextentofimprove-
ment in the structure and function of the
endothelium was signiﬁcantly different
between patients who received supple-
mentation with folic acid and subjects
who received the placebo. In fact, signiﬁ-
cant differences were observed in the val-
ues for BAD-B, BAD-RH, FMD, IMT, and
serum ET-1.
The mechanisms that underlie these
beneﬁcial effects related to supplementa-
tion of metformin treatment with folic
acid are not understood completely. In
fact, the well-known physiological effect
of folic acid is a reduction in the level of
Hcy in serum. However, its effects may
alsoinvolveotherunknownmechanisms.
In this regard, folic acid has been shown
in several clinical studies to improve en-
dothelial function independently of the
reduction of Hcy levels (21,22). Thus, al-
though serum folate levels showed a non-
signiﬁcant increase in the current study, a
direct effect of folic acid on the endothe-
lium cannot be excluded and could ex-
plain, at least partially, our ﬁndings.
On the other hand, no beneﬁcial or
adverse effects were reported on the inci-
denceofmajorcardiovasculareventsafter
supplementation with folic acid and vita-
min B complex in a high-risk population
of women over 7.3 years of follow-up
(23). A recent study (24) showed that
long-termtreatmentwithBvitaminsinan
attempt to reduce the level of Hcy did not
reduce IMT or increase FMD in patients
who had suffered strokes, even though a
modest increase in FMD without any im-
provementinthestructureofthevascular
endothelium was observed after short-
term treatment with B vitamins. Con-
versely, treatment of patients affected by
type 2 diabetes with high doses of met-
forminandfolicacidtoreduceserumHcy
levels resulted in improved elasticity of
small arteries, which suggested that folic
acid has an additional beneﬁcial effect on
the vascular system (14). This effect was
also observed in the current study of pa-
tients with PCOS.
Our ﬁndings in women affected by
PCOS may have clinical implications. In
fact,thepoweranalysiswasbasedonpre-
vious data from a meta-analysis, which
showed a hazard risk for myocardial in-
farction and stroke of up to 1.15 (95% CI
1.12–1.17) and 1.18 (1.16–1.21), re-
spectively, for a reduction of 0.1 mm in
IMT in the general population (10). In
this regard, we consider that a difference
in IMT 0.1 mm between experimental
andcontroltreatmentsismostlikelytobe
relatedtoaclinicallysigniﬁcantreduction
of long-term risk, although this can only
be proven over a long-term follow-up.
Finally, there are several limitations
to the current study that warrant consid-
Table 2—Endothelial parameters in PCOS patients treated with metformin plus supplemen-
tation with folate (experimental group) or metformin plus placebo (control group) at study
entry and after 6 months of treatment
Experimental (n  23) Control (n  24)
Baseline 6 Months Baseline 6 Months
BAD-B (mm) 3.4  0.5 2.8  0.6* 3.5  0.6 3.0  0.5*†
BAD-RH (mm) 3.7  0.4 3.4  0.6* 3.7  0.3 3.6  0.7*†
FMD (%) 14.4  1.9 16.2  2.1* 14.4  2.0 15.3  1.8*†
IMT (mm) 0.53  0.09 0.39  0.08* 0.55  0.11 0.50  0.07*†
ET-1 1.1  0.4 0.7  0.5* 1.2  0.6 0.9  0.5*†
Data are means  SD. *P  0.05 vs. baseline. †P  0.05 vs. experimental group.
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study conducted on a heterogeneous Ital-
ianpopulationwithPCOS.Second,tode-
ﬁne any short- and long-term results that
are signiﬁcant clinically, patients should
be treated and followed for a longer pe-
riod of time. Third, further studies are
needed before a clear indication can be
obtained of the dose and regimen of sup-
plementation with folic acid that is re-
quiredtooptimizethevascularbeneﬁtsof
the administration of metformin.
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